Last Updated: September 24, 2026

IHEEZO Drug Patent Profile

Name: IHEEZO Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Iheezo, and what generic alternatives are available?

Iheezo is a drug marketed by Harrow Eye and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in IHEEZO is chloroprocaine hydrochloride. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the chloroprocaine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Iheezo

A generic version of IHEEZO was approved as chloroprocaine hydrochloride by HIKMA on September 9^th, 1998.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for IHEEZO?
What are the global sales for IHEEZO?
What is Average Wholesale Price for IHEEZO?

Summary for IHEEZO

US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	58
Patent Applications:	865
Drug Prices:	Drug price information for IHEEZO
What excipients (inactive ingredients) are in IHEEZO?	IHEEZO excipients list
DailyMed Link:	IHEEZO at DailyMed

Drug patent expirations by year for IHEEZO

Pharmacology for IHEEZO

Drug Class	Ester Local Anesthetic
Physiological Effect	Local Anesthesia

US Patents and Regulatory Information for IHEEZO

IHEEZO is protected by two US patents.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	IHEEZO	chloroprocaine hydrochloride	GEL;OPHTHALMIC	216227-001	Sep 27, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
Harrow Eye	IHEEZO	chloroprocaine hydrochloride	GEL;OPHTHALMIC	216227-001	Sep 27, 2022		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for IHEEZO

See the table below for patents covering IHEEZO around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Australia	2018332212		⤷ Start Trial
Brazil	112020003095		⤷ Start Trial
Canada	3070336		⤷ Start Trial
Chile	2020000665		⤷ Start Trial
China	111163756		⤷ Start Trial
Colombia	2020002985		⤷ Start Trial
Costa Rica	20200133		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.